Stock Analysis, Dividends, Split History

MGEN / Miragen Therapeutics financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.62
Volume179,200.00
Market Cap ($M)193.53
Enterprise Value ($M)143.14
Book Value ($M)67.67
Book Value / Share2.21
Price / Book2.58
NCAV ($M)67.01
NCAV / Share2.19
Price / NCAV2.61
Share Statistics
Common Stock Shares Outstanding 22,568,006
Common Shares Outstanding 30,172,086
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.55
Return on Assets (ROA)-6.22
Return on Equity (ROE)81.33
Balance Sheet (mrq) ($M)
Assets81.89
Liabilities14.22
Quick Ration/a
Current Ratio18.96
Income Statement (mra) ($M)
License And Services Revenue3,097,000.00
Revenue From Grants906,000.00
Sales Revenue Net4,003,000.00
Operating Income-26.53
Net Income-26.51
Earnings Per Share Basic And Diluted-1.38
Cash Flow Statement (mra) ($M)
Cash From Operations-28.17
Cash from Investing1.03
Cash from Financing1.03
Identifiers and Descriptors
CUSIP60463E103
Central Index Key (CIK)1590750
Related CUSIPS
826640203 826640104

Split History

Stock splits are used by Miragen Therapeutics to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Your Daily Pharma Scoop: Kamada Phase 3 Approved, Vivus Positive, IsoRay Down

2018-07-12 seekingalpha
CHMP on board with design of late-stage study of Kamada's inhaled AAT for AATD; shares up 4% premarket (25-9)

10 Top Stock Ideas to Beat the Blues

2018-07-06 investorplace
The market isn’t looking cheery right now. In between choppy trading conditions and market pullbacks, who knows where to turn for the remaining half of 2018? However, there are still gems to be found. You just have to be more selective, and more active in your research. (60-0)

miRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good afternoon everyone, and welcome to the miRagen Therapeutics First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. And as a reminder, today's call is being recorded. (43-0)

BRIEF-Miragen Therapeutics Announces New Data Showing Administration Of MRG-110 Improved Tissue Perfusion And Wound Healing

2018-04-27 reuters
* MIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SHOWING ADMINISTRATION OF MRG-110 IMPROVED TISSUE PERFUSION AND WOUND HEALING IN LATE STAGE PRECLINICAL STUDIES (43-0)

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia. (158-3)

CUSIP: 60463E103